MedTrace Logo

Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients

NCT02939079 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-05-14

Study results available
· View outcomes & findings →

Summary

This study evaluates the effect of adding fish oil to Fingolimod on some serum cytokines in patients with Relapsing-Remitting Multiple Sclerosis.

Conditions

Interventions

DRUG

Fingolimod

Produced by Osveh ® Pharm Company in Iran

DIETARY_SUPPLEMENT

Fish Oil

produced by Zahravi ® Pharm Company in Iran

DRUG

Placebo (for Fish Oil)

placebo capsules to mimic Fish Oil 1 g capsules

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    collaborator OTHER

  • Isfahan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Shaygannejad Shaygannejad, M.D. · Isfahan University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-09-30
Completion
2016-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02939079 on ClinicalTrials.gov